Pfizer is adding follow-on biologics to pipeline

04/27/2010 | Wall Street Journal, The

Pfizer is working to boost its biotech business by developing new versions of blockbuster treatments, including formulations of blood cancer drug Rituxan and rheumatoid arthritis medicine Enbrel that require fewer injections. The company is using Trubion Pharmaceuticals' technology to tailor the "bio-betters," some of which are in midstage development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA